Phase I-II Clinical Study of Fumalate Orbitezine Enteric-Coated Pellets Capsules (SM-1) Combined with Temozolomide in the Treatment of Recurrent High-Grade Gliomas(Shenzhen Zhenxing Pharmaceutical Technology Co., Ltd.)
李文斌, 首都医科大学附属北京天坛医院肿瘤综合治疗中心主任
LIWenbin, Director of the Comprehensive Cancer Treatment Center,Beijing Tiantan hospital, Capital, Medical University
Phase II (Phase IIb) Clinical Study of LJR001 Proximod, a Highly Selective S1PR1 Agonist, for the Treatment of Rheumatoid Arthritis(Longivitron（Suzhou）Biotech Co., Ltd.)
李春, 北京大学人民医院风湿免疫科主任医师
LI Chun, Chief Physician, Department of Rheumatology and Immunology, Peking University People's Hospital
14:40 - 15:00
项目 3
Project 3
原研新药千层纸素片 ⅠⅡ期临床研究（南京芩领医药科技有限公司）
Phase I/II Clinical Trial of the Original Innovative Drug Oroxylin A Tablets (Nanjing Qinling Pharmaceutical Technology Company Limited)
秦叔逵, 中国药科大学基础医学与临床药学院院长
QIN Shukui, Dean of School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
15:00 - 15:20
项目 4
Project 4
AI驱动研发新范式：EG-501获突破性临床数据，成功攻克NPSLE认知障碍
AI-Driven R&D Yields Breakthrough: EG-501 Shows Positive Clinical Data in Addressing Cognitive Impairment in NPSLE
李长青, 埃格林医药联合创始人、首席医学官
Charles Lee, Co-founder, Chief Medical Officer of Evergreen Therapeutics
15:20 - 15:40
项目 5
Project 5
世和一号®：全球首个中美欧三认证肿瘤NGS大Panel检测试剂盒临床试验数据首发
GENESEEQPRIME®：World's First Tumor NGS Broad Panel Kit with Triple Certifications from NMPA, FDA, and CE
汪笑男, 南京世和基因生物技术股份有限公司联合创始人、首席技术官
WANG Xiaonan, Founder and CTO of Nanjing Geneseeq Technology Inc.
15:40 - 16:00
项目 6
Project 6
中国本土首个酶替代疗法产品-戈芮宁临床数据分享
First Domestic ERT Product-Gaurunning Clinical Research Data Introduction
沈菊平, 北海康成制药有限公司首席运营官
Joe SHEN, COO of CANbridge Pharmaceuticals Inc.
16:00 - 16:20
项目 7
Project 7
溶瘤腺病毒YH01注射液的开发及临床应用
Development and Clinical Application of Oncolytic Adenovirus YH01 Injection
黄映辉, 苏州映辉医药科技有限公司董事长
HUANG Yinghui, Chairman of the Board,Suzhou Infinory Pharmaceuticals, LLC
16:20 - 16:40
项目 8
Project 8
HTD1801：中国源头创新药物在心血管-肾脏-代谢（CKM）治疗领域的突破与展望
HTD1801: A Breakthrough China-Origin Therapeutic in Cardiovascular-Kidney-Metabolic (CKM) Diseases
高丽萍, 君圣泰医药董秘&副总经理
Nadia GAO, Company Secretary & Deputy General Manager, HighTide Therapeutics.
16:40 - 17:00
项目 9
Project 9
新一代HIV整合酶抑制剂Asuptegravir (ASU) Ⅱ期临床结果
Phase II Clinical Results of Asuptegravir (ASU), a New-generation HIV Integrase Inhibitor
傅和亮, 江苏艾迪药业集团股份有限公司董事长、首席科学官
FU Heliang, CSO and Chairman, Jiangsu Aidea Pharmaceutical Group Co., Ltd.
会议咨询